CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
晚期非小细胞肺癌患者接受改造 CAR-NK 治疗后发生细胞因子释放综合征：一例病例报告
英文原题：Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report.
查看英文原题
Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）作为一种免疫细胞疗法，近年来在血液系统肿瘤中产生了优异的临床疗效。其中，CAR-NK（自然杀伤）疗法比CAR-T 细胞疗法显示出更好的疗效和更低的毒性。在我们的II期临床试验中，对晚期非小细胞肺癌患者施用嵌合共刺激转换受体（CCCR）-NK92细胞，在细胞和动物实验中被证明有效。然而，我们观察到细胞因子释放综合征（CRS）的发生，这是一种罕见且意外的副作用，此前在CAR-NK治疗中从未报道过。在此，我们详细报告该患者的病例，强调在NK细胞治疗中关注CRS的必要性，并提出可最大限度减少潜在毒性的改进建议。
展开英文摘要原文
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years. Among them, the CAR-NK (natural killer) therapy has shown better efficacy, and less toxicity, than chimeric antigen receptor T-cell (CAR-T) therapy. In our phase II clinical trials, administering chimeric costimulatory converting receptor (CCCR)-NK92 cells on advanced non-small cell lung cancer patients proved efficacious in cell and animal experiments.
However, we observed occurrence of cytokine release syndrome (CRS), a rare and unexpected side effect, never reported before during CAR-NK therapy.
Here, we provide a detailed report of the patient's case, emphasize on the need to pay attention to CRS in NK cell therapy, and suggest improvements that will minimize potential toxicity.
论文信息
- 作者
- Zhang X、Guo Y、Ji Y、Gao Y、Zhang M、Liu Y、Zhu W、Lu P
- 单位
- Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.China
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- Cell transplantation2022 Jan-Dec
- 原文标识
- PubMed 35506155 · DOI 10.1177/09636897221094244
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →